MHRA paediatric investigation plan
Not available at present (Etrasimod L-arginine)
MHRA paediatric investigation plan MHRA-100224-PIP01-21 · Modification
Key facts
| PIP number | MHRA-100224-PIP01-21 |
|---|---|
| Product names | Not available at present |
| Active substances | Etrasimod L-arginine |
| Therapeutic areas | Gastroenterology-Hepatology |
| Conditions | Treatment of ulcerative colitis |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Jul 29, 2022 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: